{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:30:51Z","timestamp":1761129051474},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.semarthrit.2012.08.001","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T13:49:20Z","timestamp":1359035360000},"page":"474-481","source":"Crossref","is-referenced-by-count":11,"title":["Baseline Laboratory Test Abnormalities are Common in Early Arthritis but Rarely Contraindicate Methotrexate: Study of Three Cohorts (ESPOIR, VErA, and Brittany)"],"prefix":"10.1016","volume":"42","author":[{"given":"Marion","family":"Le Bo\u00ebdec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Marhadour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Jousse-Joulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymeric","family":"Binard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Marc Flipo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Le Lo\u00ebt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Fran\u00e7ois M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Saraux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2012.08.001_bib1","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","article-title":"Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"56","author":"Van Dongen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib2","first-page":"73","article-title":"Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"28","author":"Williams","year":"2010","journal-title":"Clin Exp Rheum"},{"issue":"312","key":"10.1016\/j.semarthrit.2012.08.001_bib3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"28","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0049-0172(83)90014-8","article-title":"Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature","volume":"12","author":"Groff","year":"1983","journal-title":"Semin Arthritis Rheum"},{"issue":"47","key":"10.1016\/j.semarthrit.2012.08.001_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0162-3109(00)00184-3","article-title":"Methotrexate use in rheumatoid arthritis. A Clinician's perspective","author":"Alarc\u00f3n","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib6","unstructured":"Vidal Dictionary. Paris. Vidal SA edition; 2010."},{"key":"10.1016\/j.semarthrit.2012.08.001_bib8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","article-title":"Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion","volume":"73","author":"Pavy","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib9","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib10","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib11","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/ard.2009.127225","article-title":"Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Gaujoux-Viala","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib13","first-page":"897","article-title":"Club rheumatism and inflammation. Laboratory and imaging studies used by French rheumatologists to evaluate patients with early arthritis","volume":"33","author":"Saraux","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jbspin.2007.06.001","article-title":"The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients","volume":"74","author":"Combe","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib15","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/acr.20321","article-title":"Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort","volume":"62","author":"Le Lo\u00ebt","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib16","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1529-0131(200111)44:11<2485::AID-ART428>3.0.CO;2-S","article-title":"Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later","volume":"44","author":"Saraux","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib17","unstructured":"\u3008http:\/\/whqlibdoc.who.int\/publications\/2008\/9789241596657_eng.pdf\u3009."},{"key":"10.1016\/j.semarthrit.2012.08.001_bib18","unstructured":"Critical reading of the CBC: Threshold values to be recognized as probably the major pathological and nonpathological variations. Anaes recommendations; 1999."},{"key":"10.1016\/j.semarthrit.2012.08.001_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2012.08.001_bib20","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib21","unstructured":"Diagnosis of chronic renal failure in adults. Anaes recommendations, 2003."},{"key":"10.1016\/j.semarthrit.2012.08.001_bib22","first-page":"1727","article-title":"Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis","volume":"31","author":"Kent","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.1780360307","article-title":"Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis","volume":"36","author":"Walker","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib24","first-page":"218","article-title":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis","volume":"22","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group","volume":"127","author":"Alarcon","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00124743-200206000-00002","article-title":"Assessment of renal function in rheumatoid arthritis: validity of a new prediction method","volume":"8","author":"Anders","year":"2002","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/rheumatology\/kem370","article-title":"Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study","volume":"47","author":"Karie","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5414\/CNP64315","article-title":"Is low-dose methotrexate nephrotoxic? Case report and review of the literature","volume":"64","author":"Izzedine","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.57.2.110","article-title":"Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients","volume":"57","author":"Bressolle","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1179\/acb.2006.028","article-title":"Methotrexate should not be used for patients with end-stage kidney disease","volume":"61","author":"Boey","year":"2006","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0049-0172(90)90001-V","article-title":"The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis","volume":"19","author":"Baer","year":"1990","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib32","first-page":"1516","article-title":"Anemia and renal function in patients with rheumatoid arthritis","volume":"33","author":"Wolfe","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib33","first-page":"133","article-title":"Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis","volume":"52","author":"Bertin","year":"1997","journal-title":"Therapie"},{"issue":"5 Suppl. 61","key":"10.1016\/j.semarthrit.2012.08.001_bib34","first-page":"S68","article-title":"Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients","volume":"28","author":"Pincus","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 9","key":"10.1016\/j.semarthrit.2012.08.001_bib35","first-page":"680","article-title":"AST and\/or ALT for methotrexate monitoring","volume":"38","author":"Mckendry","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib36","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib37","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3899\/jrheum.081308","article-title":"Is screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? The ESPOIR cohort study","volume":"36","author":"Guennoc","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/acr.20576","article-title":"Is routine viral screening useful in patients with recent-onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study","volume":"63","author":"Varache","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2012.08.001_bib39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","article-title":"Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities","volume":"64","author":"Yazici","year":"2005","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212002132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212002132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T02:56:41Z","timestamp":1539917801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017212002132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0049017212002132"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2012.08.001","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}